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Background: Lung cancer is the number one cause of cancer-related deaths in the United States and worldwide. The
complex protein changes and/or signature of protein expression in lung cancer, particularly in non-small cell lung cancer
(NSCLC) has not been well defined. Although several studies have investigated the protein profile in lung cancers, the
knowledge is far from complete. Among early studies, mucin5B (MUC5B) has been suggested to play an important role in
the tumor progression. MUC5B is the major gel-forming mucin in the airway. In this study, we investigated the overall
protein profile and MUC5B expression in lung adenocarcinomas, the most common type of NSCLCs.
Methods: Lung adenocarcinoma tissue in formalin-fixed paraffin-embedded (FFPE) blocks was collected and
microdissected. Peptides from 8 tumors and 8 tumor-matched normal lung tissue were extracted and labeled with
8-channel iTRAQ reagents. The labeled peptides were identified and quantified by LC-MS/MS using an LTQ Orbitrap
Velos mass spectrometer. MUC5B expression identified by iTRAQ labeling was further validated using
immunohistochemistry (IHC) on tumor tissue microarray (TMA).
Results: A total of 1288 peptides from 210 proteins were identified and quantified in tumor tissues. Twenty-two
proteins showed a greater than 1.5-fold differences between tumor and tumor-matched normal lung tissues. Fifteen
proteins, including MUC5B, showed significant changes in tumor tissues. The aberrant expression of MUC5B was further
identified in 71.1% of lung adenocarcinomas in the TMA.
Discussions: A subset of tumor-associated proteins was differentially expressed in lung adenocarcinomas. The
differential expression of MUC5B in lung adenocarcinomas suggests its role as a potential biomarker in the detection
of adenocarcinomas.
Keywords: Non-small cell lung cancer, Lung adenocarcinoma, Expression of mucin5B, Quantitative proteomics and
iTRAQ labeling, ImmunohistochemistryIntroduction
Lung cancer is the number one cause of cancer-related
deaths in the United States and worldwide [1]. Non-small
cell lung cancer (NSCLC) accounts for approximately 80-
85% of all lung cancers [1,2]. Among NSCLC subtypes,
adenocarcinoma (approximately consisting of 60 to 70% of* Correspondence: qli23@jhmi.edu
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reproduction in any medium, provided the orall NSCLC), has been markedly increasing in incidence
over recent years [1,2]. Currently, targeted therapies have
progressed rapidly, based upon the discovery of novel mo-
lecular markers such as mutations in EGFR (epidermal
growth factor receptor), KRAS (V-Ki-ras2 Kirsten rat sar-
coma viral oncogene homolog) genes and ALK (anaplastic
lymphoma kinase) rearrangements [3-5], however, the
overall progression-free survival rate of lung cancer pa-
tients is still suboptimal [6].
Lung cancer development is a multistep process charac-
terized by genetic alterations and subsequently abnormalhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cellular proteins, such as those associated with intracellu-
lar organelles or located on cell surfaces and secreted into
the extracellular environment, play important biological
roles in the regulation of cell growth and differentiation.
In lung tissue, protein expression directly reflects the
physiological and/or pathological status of the lung paren-
chyma [9-12]. Several recent studies have discovered that
many proteins are differentially expressed in lung cancers
[13-18]. The complex protein changes and/or signature of
protein expression, particularly those associated with
NSCLC, still need to be further defined.
Among these potential protein biomarkers, the abnor-
mal expression of mucin proteins in lung cancers is par-
ticularly interesting. Mucin proteins are a family of high
molecular weight glycoproteins, which are expressed by
epithelial cells and/or goblet cells in the airway [19]. Both
secretory and membrane-associated mucin proteins play
important roles in the regulation of normal lung functions
and are involved in many lung diseases [19,20]. For ex-
ample, they are involved in the innate immune defense
system of the lung to protect the airway against environ-
mental toxins [19]. The overexpression of mucin proteins
has been found in many chronic lung diseases, such as
asthma, chronic obstructive pulmonary diseases and cystic
fibrosis [19]. Although more than 20 mucin genes and re-
lated proteins are identified in human [19-21], the main
mucin genes in lung trachoebronchial tree are MUC5B,
MUC5AC, and MUC4 [21]. An early study of airway
mucin gene expression has demonstrated that MUC5 was
overexpressed in NSCLCs; and the elevated level of
MUC5 was associated with the early recurrence of the
tumor and poor prognosis of patients [22]. A recent study
has shown that alteration in the expression of MUC1,
MUC5AC, and MUC6 are correlated with p53 gene ab-
normalities in a subtype of lung adenocarcinomas [23].
However, potential role of MUC5B is still not fully under-
stood in lung cancers.
Recent advances in proteomics have provided a novel
approach to characterize the protein profile in lung
cancer, such as high-content quantitative proteomics
using LC-MS/MS (liquid chromatography tandem mass
spectrometry) and iTRAQ (isobaric tags for relative
and absolute quantitation) labeling [24,25]. These tech-
niques have an increased sensitivity and throughput
capability in accurate analysis of biological samples.
For example, iTRAQ labeling technique, using stable
isotope to label samples, allows for an accurate meas-
urement of the peptide abundance in biological sam-
ples by direct comparison of light and heavy peptides
in the same spectrum, whereas, the LC-MS/MS method
determines the peptide abundance by spectral count
based on the number of redundant spectra for each
protein. The combination of these techniques couldincrease the detection of low abundance proteins in
biological samples.
In this study, we investigated the protein profiles, in-
cluding the expression of MUC5B in lung adenocarcin-
omas using highly sensitive iTRAQ labeling approach, and
further validate our observations by immunohistochemis-
try (IHC) using lung adenocarcinoma tissue microarray
(TMA). The purpose of our study is to investigate the ex-
pression of tumor-associated proteins and their potential
roles in lung adenocarcinomas.
Material and methods
Materials
Sodium periodate (Bio-Rad, Hercules, CA), Tris (2-carbox-
yethyl) phosphine (TCEP) (Pierce, Rockford IL), sequen-
cing grade trypsin (Promega, Madison, WI), C18 columns
(Waters, Sep-Pak Vac), α-cyano-4-hydroxycinnasmic acid
(CHCA) (Agilent, Palo Alto, CA), MALDI 4700 mass cali-
bration standards (Applied Biosystems, Foster City, CA),
and other chemicals were purchased from Sigma-Aldrich.
iTRAQ reagent and mass calibration standards were from
Applied Biosystems (Foster City, CA); BCA assay kit was
from Pierce (Rockford, IL); SCX columns and C18 resin
were from Sepax (Newark, DE).
Lung cancer sample collection and tumor tissue
microarray (TMA) construction
Eight lung adenocarcinomas, including four cases each of
pathological stage 1 (pT1) and stage2 (pT2) tumors, and 8
cases of tumor-matched normal lung tissues were obtained
from surgical resected specimens at the Johns Hopkins
Hospital. All tumors and tumor-matched normal lung tis-
sues were fixed in formalin and embedded in paraffin prior
to proteomic analysis.
Tumor tissue microarrays (TMA) were constructed with
independently collected 45 cases of lung adenocarcin-
omas. Represented on arrays were 24 cases of pT1, 18
cases of pT2, two cases of pT3 and one case of pT4 tu-
mors. The TMA was prepared using core samples (1 mm
diameter, 3 cores per case) of paraffin tissue blocks. The
pathological stage and subtype of lung adenocarcinomas
were classified according to AJCC (American Joint Com-
mittee on Cancer) staging manual [26], WHO (World
Health Organization) and International Association for
the Study of Lung Cancer/American Thoracic Society
classification [2,27]. All tumor samples were annotated
with available clinical information in a manner that pro-
tected the patient identity.
Protein and peptide extraction from tumor tissue for
proteomic analysis
For proteomic analysis, the formalin-fixed paraffin-
embedded (FFPE) tumor tissue and tumor-matched
normal lung tissue were cut into 10 micron section and
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dissection and protein extraction.
To recover protein, hydration step was performed. The
tumor tissue section on glass slide was incubated with xy-
lene for 15 min twice, 100% ethanol for 5 min, 90% ethanol
for 5 min, 80% ethanol for 5 min, then rinsed with distill
H2O for 30 second twice. The rehydrated tumor tissue was
microdissected and collected into a centrifuge vial with
25 μl of PBS buffer. Tumor tissue was sonicated for 5 min
on an ice bath and centrifuged at 13,200 rpm for 5 min.
The protein concentration in the supernatant was measured
using BCA protein assay kit (Thermo Fisher Scientific Inc.,
Rockford, Illinois). For protein digestion, 10 μg of proteins
(20 μl in volume) was first denatured in 90 μl of 8 M urea,
0.4 M NH4HCO3, and 0.1% SDS for 1 hour at 60°C. The
proteins were then reduced by incubating with 10 μl of
120 mM Tris(2-carboxyethyl) phosphine for 30 min and
alkylated by mixing with 10 μl of 160 mM iodoaceta-
mide at room temperature for 30 min in the dark.
Sample was diluted by 200 μl of trypsin digestion buffer
(100 mM Tris–HCl, pH 7.5) containing 2 μg of trypsin at
37°C overnight. The digested peptides were purified with
C18 desalting columns and dried using SpeedVac.
iTRAQ labeling of peptides in lung adenocarcinoma
The iTRAQ (isobaric tags for relative and absolute
quantitation) 8-plex reagent was dissolved in 70 μl of
methanol. 10 μg of tryptic peptide of each sample was
added into 20 μl of iTRAQ dissolution buffer, then
mixed with 70 μl of iTRAQ 8-plex reagent and incu-
bated for 1 hour at room temperature. After iTRAQ la-
beling, the reaction solution was cleaned up by SCX
column. Then, labeled peptides were dried and resus-
pended into 10 μl of 0.4% acetic acid solution prior to
mass spectrometry analysis.
Mass spectrometry analysis
For protein quantification by spectral count, each peptide
mixture was analyzed using LC-MS/MS (liquid chroma-
tography tandem mass spectrometry) by the LTQ ion trap
mass spectrometer (Thermo Finnigan, San Jose, CA). Dur-
ing the assay, 10 μl (10 μg) peptides were injected into a
peptide cartridge packed with C18 resin, and then passed
through a 10 cm × 75 μm i.d. microcapillary HPLC (μLC)
column packed with C18 resin. The effluent from the μLC
column entered an electrospray ionization source in which
peptides were ionized and passed directly into the mass
spectrometers. A linear gradient of acetonitrile from 5%–
32% over 100 min at flow rate of approximately 300 nL/
min was applied. During the LC-MS mode, data was ac-
quired in the m/z range of 400 and 2000.
Mass spectrometry analysis was performed using a data
dependent analysis of the top ten precursors and a dy-
namic exclusion of 30 seconds. The data was acquired at30,000 resolution for the precursor scans and 7500 for
MS/MS. Target values of 1e6 for MS and 1e5 for MS/
MS were set with maximum injection time of 100 and
300 milliseconds, respectively. Data was acquired with
Monoisotopic Precursor Selection (MIPS) and Predictive
AGC enabled.
Analysis of iTRAQ labeled peptides using HPLC-Orbitrap-MS
platform
iTRAQ labeled peptide was analysed in the same setting
as described above. Peptides identification by LC-MS
was performed using an Orbitrap MS/MS (Thermo
Fisher Scientific Inc., Rockford, Illinois) interfaced with
a 2D nanoLCsystem (Eksigent, Dublin, California). 10 μl
of pooled peptides (10 μg) were loaded on a self packed
C18 column (75 μm ID × 10 cm, Magic C18 5 μm,
100A), and gradient eluted over 100 minutes at 300 nL/
minute into the mass spectrometer. The HPLC mobile
phase A and B were 0.2% formic acid in HPLC grade
water and 0.2% formic acid in HPLC grade acetonitrile,
respectively. The mobile phase B was increased from 5%
to 40% in 90 min.
Peptide identifications
The acquired data was searched against the Homo sapiens
taxonomy of the RefSeq database (Version 40, 04/16/
2010) using the Mascot (Matrix Science version 2.2.0)
search algorithm within Proteome Discoverer (Thermo
Scientific version 1.1). The data was searched with two
missed cleavages allowed and a tolerance of 15 ppm on
the precursors and 0.02 daltons on the fragment ions.
Modifications allowed included carbamidomethyl of cyste-
ines set to static. Data was also searched against a decoy
database and filtered to a 1% false discovery rate (FDR).
Immunohistochemistry (IHC)
IHC studies were performed using two lung adenocarcin-
oma TMAs. The sections were cut at 4 microns and
deparaffinized prior to performing IHC. After treatment
with antigen retrieval buffer (Dako, California) at 70°C for
40 minutes, slides were incubated with mouse monoclonal
antibody anti-human MUC5B (clone 19.4E) at 1:200 dilu-
tions for 1 hr. (Abcam, Cambridge, Massachusetts). After
washing, a secondary antibody conjugated with peroxidase
was applied to detect and visualize the specific antigen-
antibody complexes using LASB System-HRP assay kit
(Dako, California). Staining of MUC5B was scored semi-
quantitatively using a four tier system: 0, undetectable (0%
positive cells); 1+, focally positive (<10% positive cells); 2+,
moderately positive (<50% positive cells), and 3+, intensely
positive (more than 50% positive cells). Care was taken
not to interpret entrapped normal bronchial epithelium or
pulmonary macrophages as positive for tumor staining.
Appropriate controls were also included in the assay.
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p value. If the alpha value was less than 0.05, it was con-
sidered statistically significant (p < 0.05).Results
Clinical information
A total of eight adenocarcinoma and tumor-matched
normal control lung tissues were used for the proteomic
analysis. The clinical information of these cases was
summarized in Table 1. On lung adenocarcinoma TMA,
a total of 45 cases were included. The subtypes of tu-
mors were as follows: adenocarcinoma with papillary
features (16 cases), adenocarcinoma NOS (13 cases), mu-
cinous adenocarcinoma (6 cases), true papillary adenocar-
cinoma (6 cases) [28] and non-mucinous adenocarcinoma
with lepidic pattern (formerly bronchioloalveolar adeno-
carcinoma, 4 cases). The representative morphology of a
lung adenocarcinoma is shown in the Figure 1. In our
study, the patients’ age ranged from 48 to 83 years with a
median of 66.5 years. The male to female ratio was 1:1.37
(19 males and 26 females). 71.1% patients (32 of 45 cases)
were current or ex-smokers. The average size of tumors
was 3.56 cm (range from 0.7 to 12 cm).
Protein identification and profile in lung
adenocarcinoma tissues
The quantitative proteomic analyses are schematically il-
lustrated in Figure 2 and consist of following steps: (1)
tumor tissues were microdissected and proteins were ex-
tracted; (2) total proteins were further digested into pep-
tides; (3) the peptides were labeled with 8-plex iTRAQ
reagents; and (4) peptides were identified and quantified
by LC-MS/MS, and spectral count. Peptides from four
cases of pT1 tumor cases were labeled with iTRAQ chan-
nel 117, 118, 119, 120, while peptides from pT2 tumor
cases were labeled with channel 113, 114, 115, and 116.
The quantitative results were generated from the peak
area of MS2 peaks of fragments (m/z from 113 to 121) of
iTRAQ reagents. The LC-MS/MS method determines theTable 1 Clinical characterization of lung adenocarcinomas
Cases Age (years) Sex T size (cm)
1 67 M 2.4
2 69 F 1.5
3 82 M 1.8
4 55 F 1.5
5 67 M 12.0
6 64 F 9.0
7 78 F 4.0
8 77 M 2.5
T: Tumor. pT: Pathological stage of tumor. R: Right. L: Left or lower or lobe. U: Uppepeptide abundance by comparing the intensity of the same
peptide peak in multiple LC-MS/MS runs. Quantitation of
protein abundance by spectral count is based on the num-
ber of redundant spectra acquired for each protein from
different samples in the LC-MS/MS analyses. We were
able to identify and quantify 210 proteins using iTRAQ la-
beling [29].
We then determined and quantified the protein changes
in different stage of tumors by iTRAQ. To determine the
proteins with abundance changes in two stages, a histo-
gram was used to generate the number of proteins in dif-
ferent abundance ratio. The threshold was set as < 0.7 and
>1.3 for iTRAQ labeling. The means of pT1 and pT2 sam-
ples were used and the ratio of the means of pT1 to pT2
was calculated. Most of proteins (188 proteins, 89.5%)
were distributed within one standard deviation from the
mean and were considered as unchanged. Proteins that fell
out of one standard deviation of the distribution curve
were considered as with significant changes. A total of 22
proteins were identified between pT1 and pT2 tumors.
These proteins were summarized in the Table 2.
Further identification and quantitative analysis of MUC5B
in tumor tissue
We further analyzed the level of MUC5B in different
stages of tumors and tumor-matched normal lung tissues
using LC-MS/MS spectrum counts (Figure 3 and Figure 4).
Our data demonstrated that the abundance of MUC5B in
tumor tissue was significantly more than that in tumor-
matched normal tissue regardless of tumor stages.
To evaluate expression and cellular localization of
MUC5B protein in lung adenocarcinoma tissues, we per-
formed IHC using mouse anti-MUC5B monoclonal anti-
body (clone19.4E), which reacts with MUC5B and does
not react with MUC5A or MUC5C. The overall expres-
sion of MUC5B in 45 lung adenocarcinoma tumors is
summarized in Figure 5 and Table 3. Of 45 tumors, 13
cases (28.9%) were negative for MUC5B expression, 8
cases (17.8%) were weakly positive, 13 cases (28.9%) and
11 cases (24.4%) were focally and intensely positive. TheT stage Location of tumor Surgery
pT1 RLL Lobectomy








Figure 1 Histomorphology of lung adenocarcinomas.
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the cytoplasmic membrane. Among different subtypes
of adenocarcinomas, MUC5B was detected in 25% (1 of
4 cases) of adenocarcinomas with lepidic patterns,
62.5% (10 of 16 cases) of adenocarcinoms with papillaryFigure 2 Diagram of work flow for determination of tumor-associatedfeatures, 66.7% (4 of 6 cases) of true papillary adenocar-
cinomas, 84.6% (11 of 13 cases) of adenocarcinomas
NOS, and 100% (6 of 6 cases) of mucinous adenocarcin-
omas. In normal lung parenchyma, alveolar macro-
phages showed some cytoplasmic staining of MUC5B.proteins in lung adenocarcinoma tissues.
Table 2 Proteins with differential expression in lung adenocarcinomas
Accession Proteins MW [kDa] Coverage Ratio of T2/T1 tumor
gi52426774 MHC, class II, DR alpha 28.6 5.51 3.109794973
gi110611233 Alpha 1 type XVIII collagen isoform 2 135.4 1.27 2.876066498
gi4504347 Hemoglobin subunit alpha 15.2 15.49 2.672828838
gi169217452 HLA class II histocompatibility antigen, DRB1-4 beta chain 25.7 8.97 2.548467326
gi56682959 Ferritin heavy chain 21.2 5.46 2.376697349
gi66346695 Fibrillin-2 314.6 0.24 2.288948591
gi40786436 Eukaryotic translation initiation factor 4A1 46.1 2.46 2.094114969
gi87196339 Collagen, type VI, alpha 1 108.5 0.88 1.986732711
gi4557733 Latent transforming growth factor beta binding protein 2 194.9 4.17 1.959638153
gi169210992 Hypothetical protein LOC100131693 25.1 3.69 1.909014562
gi24797076 MHC, class II, DR beta 1 29.1 3.49 1.879322964
gi207028935 Microfibrillar-associated protein 2 isoform b 20.7 5.49 1.846061192
gi4502107 Annexin A5 35.9 6.25 1.785327852
gi53946395 Tenascin 240.7 2.04 1.758381294
gi4758606 Integrin-linked protein kinase 51.4 2.43 1.673110304
gi13775595 Tryptase alpha/beta 1 30.5 6.55 1.638626466
gi5453678 Epididymal secretory protein E1 16.6 10.60 1.515388592
gi4557759 Myeloperoxidase 83.8 1.34 0.557022924
gi28827801 Anterior gradient protein 3 19.2 6.63 0.475747013
gi54607120 Lactotransferrin 78.1 1.27 0.334947079
gi124248516 Alpha-defensin 1 10.2 19.15 0.272535866
gi53945878 Mucin-5B 596.3 1.11 0.246384026
Figure 3 MS spectrum of mucin5B in pT1 lung adenocarcinomas and tumor-matched normal lung tissues.
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Figure 4 MS spectrum of mucin5B in pT2 lung adenocarcinomas and tumor-matched normal lung tissues.
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The lung parenchyma and alveolar space are complex
structures that contain numerous cellular proteins. In
addition, lung cancer involves numerous genetic abnor-
malities with turn-on and turn-off expression at differentFigure 5 Immunostain of mucin 5B in lung adenocarcinomas.stage of the tumor. In our study, in order to increase the
detection of tumor associated proteins, different patho-
logical stages of tumor tissues were included. Using the
iTRAQ labeling approach, a total of 1288 peptides from
210 proteins were identified and quatified. Among them,




IHC IHC IHC IHC
Staining Staining Staining Staining
Negative 1+ 2+ 3+
pT1 (n = 24) 5 (20.8%) 4 (16.7%) 7 (29.2%) 8 (33.3%)
pT2 (n = 18) 6 (33.3%) 3 (16.7%) 6 (33.3%) 3 (16.7%)
pT3/4 (n = 3) 2 (66.7%) 1 (33.3%)
Total (n = 45) 13 (28.9%) 8 (17.8%) 13 (28.9%) 11(24.4%)
Li et al. Clinical Proteomics 2013, 10:15 Page 8 of 10
http://www.clinicalproteomicsjournal.com/content/10/1/1522 proteins showed greater than 1.5-fold differences be-
tween stage pT1 and pT2 tumors. A subset of proteins,
such as fibrillin-2, ferritin, eukaryotic translation initiation
factor 4A1 (eIF-4A1), annexin A5, mucin-5B (MUC5B),
alpha-defensin 1 and anterior gradient protein 3 (hAG 3),
are interesting.
In our study, the detection of MUC5B in tumor tissue is
particularly interesting. Mucins (MUC) are a family of
high molecular weight, heavily glycosylated proteins. In
human, more than 20 mucin genes and related proteins
are identified [19-21]. They can be divided into two major
groups, membrane-associated mucin proteins including
MUC1, MUC3, MUC4, MUC12, MUC13, MUC16 and
MUC17; and secreted mucin proteins including both gel-
forming such as MUC2, MUC5AC, MUC5B, MUC6 pro-
teins, and non-gel-forming MUC7 protein [19-21]. Both
types of mucins play important roles in the regulation of
cellular functions such as formation of physical barrier,
maintenance homeostasis of extracellular environment,
and regulation of cell growth and differentiation. In cancer
cells, mucin proteins also play important roles in tumor
cell growth, invasion and metastasis [20]. Overexpression
of MUC1 has been associated with potential risk of metas-
tasis of colon cancer [30], pancreatic cancer [31] and oral
squamous cell carcinoma [32]. The expression of MUC2
has been identified in pancreatic and liver cancer [33].
MUC4 protein contains an EGF (epidermal growth fac-
tor)-like motif on the extracellular domain and has been
linked to the EGF signaling pathway [34,35]. It has been re-
ported that main mucin genes in lung trachoebronchial tree
are MUC5B, MUC5AC, and MUC4 [21]. Among them,
MUC5B is the major gel-forming mucin which forms a
protective matrix in the airway. In normal adult lung paren-
chyma, the expression of MUC5B follows a distinct pattern.
It is predominately expressed in the mucus producing cells
in the large airway; the intensity of its expression is de-
creased from tracheobronchus towards the bronchioles,
with no expression in small bronchioles and pneumocytes
[36]. A few recent studies have shown that MUC5B is also
frequently expressed in lung mucinous adenocarcinoma,
and the expression of MUC5B is inversely correlated with
the differentiation of the tumor [37]. Abnormal expressions
of MUC1, MUC5 and MUC6 have also been related to theaggressive behavior of lung adenocarcinoma [22,23,38]. In
our study, we found elevated expression of MUC5B in lung
adenocarcinoma by iTRAQ labeling and further validated
by IHC using lung adenocarcinoma TMAs. In the iTRAQ
labeling study, it seems that there is a loss of MUC5B
expression in higher stage of tumors (stage II lung adeno-
carcinomas), however, we will not be able to draw a conclu-
sion due to a small set of cases in our study. We further
performed an IHC assay using mouse anti-MUC5B mono-
clonal antibody (clone19.4E) to evaluate the expression of
MUC5B using TMA. The monoclonal antibody in our
study reacts with MUC5B, but does not react with MUC5A
or MUC5C. We found that the expression of MUC5B was
detected in 32 of 45 tumors (71.1%). Of 32 tumors, 8 cases
(17.8%) were weakly positive, 13 cases (28.9%) and 11 cases
(24.4%) were focally and intensely positive. The predomin-
ant location of MUC5B in tumor cells was in the cytoplasmic
membrane. Among different subtypes of adenocarcinomas,
MUC5B was detected in 25% (1 of 4 cases) of adenocarcin-
omas with lepidic patterns, 62.5% (10 of 16 cases) of adeno-
carcinoms with papillary features, 66.7% (4 of 6 cases) of true
papillary adenocarcinomas, 84.6% (11 of 13 cases) of adeno-
carcinomas NOS, and 100% (6 of 6 cases) of mucinous
adenocarcinomas. Our data demonstrates that MUC5B is
abnormally expressed by most of tumors, and suggests that
it may be a potential biomarker for lung adenocarcinomas.
Furthermore, we also found several proteins were differ-
entially expressed in tumors, such as fibrillin-2, ferritin,
hypothetical protein LOC100131693, eIF4A, annexin A5,
anterior gradient-2 (hAG-2) and alpha-defensin-1. Fibrillin-
2 is the key component of human elastic fiber in extracellu-
lar matrix. Aberrant methylation of its gene has been found
in 53% of lung adenocarcinoms and has been correlated
with large tumor size, nodal metastasis and advanced
tumor stage in NSCLC [39]. Ferritin is an iron-binding pro-
tein; elevated serum level has been detected in advanced
lung cancer patients, overexpression of this protein has
been found in tumor tissue and has been reported to cor-
relate with nodal metastasis in NSCLC [40]. Hypothetical
protein LOC100131693 belongs to a group of proteins that
are not described at the protein level but rather predicted
from cDNA sequences [41]. It is of special interest as it
may represent a new marker or marker for development
of tumor vaccine, particularly when found in tumor tis-
sue. eIF4A plays an important role in the regulation of
eIF4E-eIF4G complex during the eukaryotic translation
initiation in the AKT-mTOR signal pathway, which in-
volves cell growth, angiogenesis, invasion, survival [42].
Annexin A5 is a phospholipid binding protein and binds
to phophatidylserine. During early events of apoptosis,
annexin A5 binds to phosphatidylserine on the cell mem-
brane, thus regulates programmed cell death. It has been
found to be overexpressed in p-XSC treated mice lung
adenocarcinoma [43]. Interestingly, the use of isotopic
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death has been suggested to be important in monitoring pa-
tient’s response to chemotherapy [44]. The human anterior
gradient-2 (hAG-2) gene has been proposed an oncogene
for NSCLC. The hAG-2 is expressed in lung squamous cell
carcinoma [45]. In the screening of breast tumor tissue
using reverse transcription-PCR and immunohistochemistry
with affinity purified anti-hAG-2 antibodies, Liu et al. re-
ported that the presence of hAG-2 mRNA and protein were
associated with estrogen alpha (ERA)-positive carcinomas
[46]. There were no differences in the mean latency periods
of tumor formation when an expression vector bearing
hAG-2 cDNA was introduced into benign rat mammary
tumor cells, but metastases occurred at high rates in the
lung of animals receiving the hAG-2 transfectants (77–92%
of animals with primary tumors, compared with 0% in
the control groups). Their results suggest that hAG-2 may
be a potential marker related to cancer metastasis. Alpha-
defensin-1, also known as the human neutrophil peptides
(HNP1-3), is a small cationic peptide found in neutrophil
granules. Alpha-defensin showed cytotoxicity to various
types of eukaryotic and tumor cells. The mechanism of
alpha-defensin induced cell damage and death involves re-
lease of cytochrome c from mitochondria, which is the key
event of mitochondria-mediated apoptosis; it has been found
to inhibit the growth of human lung adenocarcinoma xeno-
graft in nude mice [47]. The Biological role of these proteins
in lung adenocarcinomas need to be further investigated.
A recent study by Kikuchi T, et al [48] has shown that
3513 proteins were identified from pooled lung adenocar-
cinoma tissues using the shotgun proteomic method, and
they further validate a few candidate proteins using mul-
tiple reactions monitoring MS, IHC staining and Western
blotting analysis. In comparison to their study, we have also
identified similar proteins in tumor tissues using iTRAQ la-
beling approach, such as eIF, collagen type VI, tenascin, an-
terior gradient protein, MUC5B, and hemoglobin subunit
alpha BAL. In our recent study of lung airway fluid, we
have further identified a subset of proteins derived from
tumor tissue in the airway fluid specimens [29]. Taken to-
gether, these findings are important and suggest that unique
tumor-derived proteins can be identified in both lung par-
enchyma and airway fluid, and some of these proteins could
be further tested and validated as potential biomarkers for
the detection of lung adenocarcinomas.
In summary, our data demonstrate that a large num-
ber of protein changes during the lung cancer disease
process can be identified by quantitative proteomic
approaches. However, the potential role of these identi-
fied proteins need to be further validated and character-
ized. The study of protein expression in lung cancers is
also important for understanding the disease process,
assessing the tumor progression, and customizing thera-
peutic modalities for individual patients.Consent
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